Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Rehman

Allergy & Immunology Toledo, OH Medical Doctor

NPI 1699775437 CMS profile 31037

7247 W Central Ave, Suite A, Toledo, OH 43617

Open in the dashboard

General payments

$373,591

1,132 records reported · program years 2019–2025

Research payments

$25,831

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,258,635 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Syed Rehman of Toledo, OH is reported in the CMS Open Payments database as having received $373,591 across 1,132 general payments and $25,831 in research payments paid to them. Separately, studies naming them as principal investigator received $3,258,635 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,770 215
2025 Research $192 3
2024 General $42,248 161
2023 General $112,675 204
2022 General $57,081 189
2021 General $33,571 116
2020 General $20,691 93
2020 Research $6,813 1
2019 General $37,555 154
2019 Research $18,826 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Rehman
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Syed Rehman were reported at $69,770. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Syed Rehman Allergy & Immunology median Middle half National median
2019 $37,555 $594 $163–$1,512 $163
2020 $20,691 $426 $106–$1,233 $114
2021 $33,571 $638 $157–$1,708 $132
2022 $57,081 $790 $205–$1,961 $149
2023 $112,675 $852 $220–$2,147 $160
2024 $42,248 $865 $203–$2,267 $164
2025 $69,770 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $117,407 202 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $104,646 183 payments
  3. GlaxoSmithKline, LLC. $95,738 243 payments
  4. Genentech USA, Inc. $18,331 67 payments
  5. Grifols USA, LLC $16,368 37 payments
  6. Novartis Pharmaceuticals Corporation $6,720 21 payments
  7. Amgen Inc. $4,339 36 payments
  8. Shire North American Group Inc $3,498 11 payments
  9. CSL Behring $1,294 61 payments
  10. Regeneron Healthcare Solutions, Inc. $1,101 57 payments
  11. Other $4,149 214 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $316,628 127 payments
  2. Food and Beverage $20,496 866 payments
  3. Travel and Lodging $19,598 114 payments
  4. Consulting Fee $16,186 13 payments
  5. Honoraria $375 3 payments
  6. Education $308 9 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $90,885 108 payments
  2. CINRYZE $72,750 78 payments
  3. AREXVY $48,038 48 payments
  4. TAKHZYRO $30,426 54 payments
  5. TRELEGY ELLIPTA $25,966 101 payments
  6. FASENRA $19,123 37 payments
  7. Xolair Immunology $18,331 67 payments
  8. Xembify $16,112 24 payments
  9. XOLAIR Respiratory $6,535 13 payments
  10. CUVITRU $3,884 11 payments
  11. Other $17,600 648 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biotest AG $25,640 2 payments
  2. Teva Pharmaceuticals USA, Inc. $192 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,307

Median for Allergy/ Immunology: 449

Drug cost

$1,029,186

Median for Allergy/ Immunology: $169,700

Branded share of claims

50%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 12 $588,009
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 65 $123,807
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 118 $121,123
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 11 $54,978
Nucala Mepolizumab Brand 11 $37,004
Breo Ellipta Fluticasone/Vilanterol Brand 26 $14,361
Spiriva Respimat Tiotropium Bromide Brand 25 $13,324
Symbicort Budesonide/Formoterol Fumarate Brand 40 $12,308
Advair Hfa Fluticasone Propion/Salmeterol Brand 24 $9,740
Dulera Mometasone/Formoterol Brand 27 $8,548

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$586,067

Of which drugs: $535,620

Medicare patients

142

Average age 72

Services billed

22,339

97 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 51%
Diabetes 29%
COPD 26%
Ischemic heart disease 23%
Depression 20%
Chronic kidney disease 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$21,279 — —
TAKHZYRO
$16,747 12 —
Xembify
$2,278 — —
DUPIXENT
$301 — —
TRELEGY ELLIPTA
$271 118 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record